Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 15

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 15
---
 30, 2025, with an exercise price of $1.50 per share, as more fully described in the section titled “Description of Capital Stock—Warrants—New Series B Warrants;” |

| • |     | shares of common stock reserved for future issuance under our 2025 Equity Incentive                                                                                                                                                                       
 Plan, or 2025 Plan, which became effective upon the execution and delivery of the underwriting agreement for this offering, as well as any future automatic annual increases in the number of shares of common stock reserved for issuance under our 2025 
 Plan, as more fully described in the section titled “Executive Compensation—Equity Benefit Plans;” and                                                                                                                                                    |

| • |     | shares of common stock reserved for future issuance under our 2025 Employee Stock                                                                                                                                                                     
 Purchase Plan, or ESPP, which became effective upon the execution and delivery of the underwriting agreement for this offering, as well as any future automatic annual increases in the number of shares of common stock reserved for future issuance 
 under our ESPP, as more fully described in the section titled “Executive Compensation—Equity Benefit Plans.”                                                                                                                                          |

Unless otherwise indicated, all information contained in this prospectus assumes or gives effect to:

| • |     | a                                                                                                        
 -for-      reverse stock split of our common stock to be effected prior to the closing of this offering; |

| • |     | the filing of our amended and restated certificate of incorporation and the adoption of our amended and restated 
 bylaws immediately prior to the closing of this offering;                                                        |

| • |     | no exercise by the underwriters of their option to purchase additional shares of our common stock. |

9

SUMMARY FINANCIAL INFORMATION The following tables set forth a summary of our financial data as of, and for the periods ended on, the dates indicated. We have derived the summary statements of operations data for the years ended December 31, 2024 and 2023 from our audited financial statements included elsewhere in this prospectus. The following summary condensed statements of operations data for the six months ended June 30, 2025 and 2024, and the summary condensed balance sheet data as of June 30, 2025 have been derived from our unaudited condensed financial statements included elsewhere in this prospectus. Our financial statements appearing elsewhere in this prospectus have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP.